Leukemia Stocks List

Leukemia Stocks Recent News

Date Stock Title
Nov 21 TEVA Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
Nov 20 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
Nov 20 HCWB HCW Biologics prices $6.9M registered direct offering at $1.03 per share
Nov 19 TEVA Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)
Nov 19 NEO NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Nov 19 HCWB HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement
Nov 19 HCWB HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
Nov 18 HCWB Top Midday Gainers
Nov 18 HCWB Why Is Penny Stock HCW Biologics Surging On Monday?
Nov 18 ANIX Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Nov 18 HCWB HCW Biologics jumps on license agreement for immunotherapeutic product candidate
Nov 18 HCWB HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Nov 16 TEVA Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Nov 15 ADPT Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
Leukemia

Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. These white blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising problems, feeling tired, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.The exact cause of leukemia is unknown. A combination of genetic factors and environmental (non-inherited) factors are believed to play a role. Risk factors include smoking, ionizing radiation, some chemicals (such as benzene), prior chemotherapy, and Down syndrome. People with a family history of leukemia are also at higher risk. There are four main types of leukemia—acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)—as well as a number of less common types. Leukemias and lymphomas both belong to a broader group of tumors that affect the blood, bone marrow, and lymphoid system, known as tumors of the hematopoietic and lymphoid tissues.Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, in addition to supportive care and palliative care as needed. Certain types of leukemia may be managed with watchful waiting. The success of treatment depends on the type of leukemia and the age of the person. Outcomes have improved in the developed world. The average five-year survival rate is 57% in the United States. In children under 15, the five-year survival rate is greater than 60 to 85%, depending on the type of leukemia. In children with acute leukemia who are cancer-free after five years, the cancer is unlikely to return.In 2015, leukemia was present in 2.3 million people and caused 353,500 deaths. In 2012 it newly developed in 352,000 people. It is the most common type of cancer in children, with three quarters of leukemia cases in children being the acute lymphoblastic type. However, about 90% of all leukemias are diagnosed in adults, with AML and CLL being most common in adults. It occurs more commonly in the developed world.

Browse All Tags